{"id":"081f071a-fce2-5f14-817d-93a0363d2538","stable_key":"6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7:stevia-crude-pressure-null","predicate":"did_not_outperform_placebo","statement":"Crude stevioside increased from 3.75 to 15 mg/kg/day over 24 weeks did not lower blood pressure more than placebo in untreated mild hypertension.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"bf6e79f4-0cd3-55d6-99f5-14ea8ce28b3e","mechanism_event_label":"Preparation and trial design matter when comparing apparent benefits.","subject":{"id":"26d4618c-2fc0-5b2f-9033-d4ad3ce9ff22","slug":"crude-stevioside-preparation","display_name":"Crude stevioside preparation from the 2006 hypertension trial","entity_type_key":"small_molecule"},"object":{"id":"9b20520f-5cf0-5b75-96b4-a7f86df489e6","slug":"human-crude-stevioside-blood-pressure","display_name":"Human blood pressure during crude-stevioside trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"bf6e79f4-0cd3-55d6-99f5-14ea8ce28b3e","stable_key":"6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7:stevia-crude-pressure-null-event","event_type":"observed_relationship","label":"Preparation and trial design matter when comparing apparent benefits.","description":"Crude stevioside increased from 3.75 to 15 mg/kg/day over 24 weeks did not lower blood pressure more than placebo in untreated mild hypertension.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"26d4618c-2fc0-5b2f-9033-d4ad3ce9ff22","slug":"crude-stevioside-preparation","display_name":"Crude stevioside preparation from the 2006 hypertension trial","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9b20520f-5cf0-5b75-96b4-a7f86df489e6","slug":"human-crude-stevioside-blood-pressure","display_name":"Human blood pressure during crude-stevioside trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c78086c3-7657-589b-b353-1691df2d9f8f","slug":"stevia","display_name":"Stevia","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Four-week placebo run-in followed by randomized dose-escalation treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The formulation, doses, duration and population differ from the two-year trial; a direct same-condition contradiction is not established.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Stevia collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"stevia","display_name":"Stevia","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Preparation and trial design matter when comparing apparent benefits.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16775813/ · DOI 10.1002/ptr.1944","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4278b986-ee70-552c-a7a5-158ab28503e3","evidence_kind":"source_excerpt","locator":"Lines 394-400","start_line":394,"end_line":400,"excerpt":"## stevia-crude-pressure-null\nPreparation and trial design matter when comparing apparent benefits.\nCrude stevioside increased from 3.75 to 15 mg/kg/day over 24 weeks did not lower blood pressure more than placebo in untreated mild hypertension.\nModel: Four-week placebo run-in followed by randomized dose-escalation treatment.\nLimitations: The formulation, doses, duration and population differ from the two-year trial; a direct same-condition contradiction is not established.\nEvidence access: Primary abstract\nInvestigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16775813/ · DOI 10.1002/ptr.1944","model_system":"Four-week placebo run-in followed by randomized dose-escalation treatment.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"295304c9-609c-5b05-a18f-a00ab7b965ed","stable_key":"import-6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7","title":"Stevia: glycoside metabolism, taste, ion channels and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"a36a82c2f8a0a971ea43e9e742db65f45848d13ab77310c0dd6b5cd55e31fc16","revision_id":"ea0355af-a926-511a-a7f2-1750baa95a8d","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}